Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07251465 · ClinicalTrials.gov registry record
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
A clinical trial, sponsored by Pfizer.
- Active
- Registry status
- 846,279
- Enrollment target
NCT07251465: Active study, sponsored by Pfizer.
NCT07251465 is a clinical trial that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 846,279 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07251465 is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 846,279 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The information of participants will be taken from Kaiser Permanente Southern California's (KPSC) electronic health records (EHR). We will look at the EHR information for adults who meet the following points: * 18 years of age or older and a KPSC member as of 01 July 2022. * have been a KPSC member for at least one year before 01 July 2022. * have not received PCV15. * have had pneumonia or lower respiratory tract infection within 30 days of 01 July 2022. The study will begin from 01 July 2022 and will be followed through 30 June 2025. At the end of the follow-up period, the study will compare the number of pneumonia cases among people who receive PCV20 who do not receive it.
Primary Outcome
PCV20 VE against ACP calculated as (1-aHR) × 100% separately among adults aged 19-64 years with medical conditions or behavioral risk factors and among adults ≥65 years of age
Interventions
- BIOLOGICAL Receipt of PCV20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 846,279 participants |
| Start Date | 2026-01-21 |
| Est. Completion | 2026-07-31 |
What the registry record for NCT07251465 still lists
NCT07251465 is an observational study that tracks outcomes without assigning an intervention. Its 846,279 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Receipt of PCV20 is the first listed.
NCT07251465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07251465 about?
NCT07251465 is a clinical study titled "A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia". The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The ...
What is the current status of trial NCT07251465?
This trial is currently active not recruiting. The enrollment target is 846,279 participants. The study started on 2026-01-21. Estimated completion is 2026-07-31.
What interventions are being tested in trial NCT07251465?
The interventions under investigation include: Receipt of PCV20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07251465?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI